



Bioactive lignan derivatives from the stems of *Firmiana simplex*



Kyeong Wan Woo^a, Won Se Suh^a, Lalita Subedi^b, Sun Yeou Kim^{b,c}, Aejung Kim^d, Kang Ro Lee^{a,*}

^a Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-Ro, Jangan-ku, Suwon, Gyeonggi-do, Republic of Korea

^b College of Pharmacy, Gachon University, #191 Hambakmoe-ro, Yeonsu-gu, Incheon 406-799, Republic of Korea

^c Gachon Medical Research Institute, Gil Medical Center, Incheon, Republic of Korea

^d The Graduate School of Alternative Medicine, Kyonggi University, Seoul, Republic of Korea

ARTICLE INFO

Article history:

Received 25 September 2015

Revised 28 December 2015

Accepted 5 January 2016

Available online 6 January 2016

Keywords:

Firmiana simplex

Sterculiaceae

Lignan

Anti-neuroinflammatory effect

ABSTRACT

The CHCl₃ soluble fraction of the 80% MeOH extract of the stems of *Firmiana simplex* strongly inhibited nitric oxide production in lipopolysaccharide-activated BV-2 cells. A bioactivity-guided column chromatographic separation yielded two new lignans, firmianols A and B (**1–2**) together with seventeen known lignans (**3–19**). The structural elucidation of the new compounds was determined by spectroscopic methods, including 1D, 2D NMR and HR-FAB-MS. All isolated lignans were evaluated for their antineuroinflammatory effects on nitric oxide (NO) production in lipopolysaccharides (LPS)-activated murine microglia BV2 cells. Among the isolated, compounds **14** and **15** showed potent inhibitory activity against NO production (IC₅₀ 1.05 and 0.929 μM, respectively) without cell toxicity in murine microglia BV-2 cells. Compounds **11–13** and **17** also exhibited strong inhibitory effects on NO production, with IC₅₀ values ranging from 7.07 to 15.28 μM.

© 2016 Elsevier Ltd. All rights reserved.

Neuroinflammation plays a central role in most neurodegenerative diseases such as Parkinson's disease, Alzheimer disease, multiple sclerosis, and stroke, and is mediated by microglial activation.¹ Microglia cells exist in the CNS and are the major targets of microgliosis following neurodegeneration.² Following microglial activation due to injury in the brain, excessive NO is produced, which initiates a cascade of neuroinflammatory responses.³ Therefore, discovering neuroprotective drugs that inhibit NO production via activated microglia is crucial in treating neurodegenerative diseases.

In our continuing search for neuroinflammatory components from Korean medicinal plants,^{4–8} the CHCl₃-soluble fraction of *Firmiana simplex* was found to strongly inhibit nitric oxide production in lipopolysaccharide-activated BV-2 cells.

F. simplex (Sterculiaceae) is a deciduous tree that is distributed in Korea and China.⁹ It is called a Chinese parasol tree, which is characterized by large stems and leaves, and is popular as an ornamental plant.¹⁰ *F. simplex* seeds have been used to treat diarrhea and stomach disorders.¹¹ Recently, Our earlier phytochemical investigation on *F. simplex* resulted in the isolation of cytotoxic triterpenes.¹² Using bioactivity-guided isolation techniques, nineteen lignan derivatives including two new lignans (**1–2**) were further isolated from the most active CHCl₃-soluble fraction (Fig. 1). In

the present study, we report the isolation and structural elucidation of compounds **1–19** and their NO production activity.

Compound (**1**) was obtained as a colorless gum. The molecular formula of **1** was determined to be C₁₉H₁₈O₆ by the negative mode HR-FABMS data at *m/z* 341.1020 [M–H][–] (calcd for C₁₉H₁₇O₆, 341.1020). The ¹H NMR spectrum (Table 1) of **1** showed signals of 1,3,4-trisubstituted-aromatic ring protons at δ_H 6.99 (1H, d, *J* = 1.5 Hz, H-2), 6.92 (1H, d, *J* = 7.5 Hz, H-6), and 6.81 (1H, dd, *J* = 7.5, 1.5 Hz, H-5), of 1,4-disubstituted-aromatic protons at δ_H 7.27 (2H, d, *J* = 9.0 Hz, H-2', 6') and 6.80 (2H, d, *J* = 9.0 Hz, H-3', 5') of dioxymethylene at 5.95 (2H, s, –OCH₂O–), of two oxygenated methines at 4.86 (1H, d, *J* = 5.5 Hz, H-7) and 4.69 (1H, s, H-7'), of four oxygenated methylenes at δ_H 4.46 (1H, t, *J* = 9.0 Hz, H-9a), 4.03 (1H, d, *J* = 9.0 Hz, H-9'a), 3.87 (1H, d, *J* = 9.0 Hz, H-9'b), and 3.78 (1H, dd, *J* = 8.5, 5.5 Hz, H-9b), of one methine proton at 3.00 (1H, dt, *J* = 7.5, 3.5 Hz, H-8).

The ¹³C NMR spectrum (Table 2) revealed resonances for 19 carbons attributable to twelve aromatic carbons, one dioxymethylene carbon (δ_C 102.4), five oxygenated carbons (δ_C 92.7, 89.2, 87.5, 76.3, and 72.1), and one methine carbons (δ_C 62.6). The ¹H and ¹³C NMR spectra of **1** were very close to those of (+)-beechnol, which was isolated from *Zanthoxylum beecheyanum*,¹³ except that the proton and carbon signal of methine (H-8') in (+)-beechnol were absent, and instead, the resonances of oxygenated carbon at δ_C 92.7 was present in **1**. The gross planar structure of **1** was confirmed by analysis of 2D NMR experiments (¹H–¹H COSY, HMQC, and HMBC) (Fig. 2).

* Corresponding author. Tel.: +82 31 290 7710; fax: +82 31 290 7730.

E-mail address: krlee@skku.edu (K.R. Lee).


Figure 1. Chemical structures of compounds 1–19 from *F. simplex*.

Table 1

¹H NMR data of compounds 1 and 2 (CD₃OD, 700 MHz, δ in ppm, J in Hz)^a

Position	1		2	
	δ _H	HMBC	δ _H	HMBC
1	—	—	—	—
2	6.99 (d, 2.0)	4, 6, 7	7.08 (d, 2.0)	4, 6, 7
3	—	—	—	—
4	—	—	—	—
5	6.81 (d, 9.0)	1, 3	6.80 (d, 8.0)	1, 3
6	6.92 (dd, 8.5, 1.5)	2, 3, 7	6.90 (dd, 8.0, 2.0)	2, 3, 7
7	4.86 (d, 5.5)	2, 6, 8, 9, 8', 9'	4.8 (overlap)	2, 6, 8, 9, 8', 9'
8	3.00 dt (7.5, 5.5)	1, 8'	3.07 m	1, 8'
9a	4.46 (t, 9.0)	7, 8, 7', 8'	4.51 (t, 9.0)	7, 8, 7', 8'
9b	3.78 (dd, 8.5, 5.5)	—	3.81 (dd, 9.0, 6.0)	—
1'	—	—	—	—
2'	7.27 (d, 9.0)	2', 3', 4', 7'	6.80 s	4', 6', 7'
3'	6.80 (d, 9.0)	1', 3', 4'	—	—
4'	—	—	—	—
5'	6.80 (d, 9.0)	1', 3', 4'	—	—
6'	7.27 (d, 9.0)	2', 3', 4', 7'	6.80 s	2', 4', 7'
7'	4.69 s	8, 9, 2', 8', 9'	4.75 s	9, 1', 2', 8', 9'
8'	—	—	—	—
9'a	4.03 (d, 9.0)	7, 8, 7', 8'	4.14 (d, 9.0)	7, 8, 7', 8'
9'b	3.87 (d, 9.0)	—	3.91 (d, 9.0)	—
1''	—	—	—	—
2''	—	—	7.03 br s	4'', 6'', 7''
3''	—	—	—	—
4''	—	—	—	—
5''	—	—	6.77 (d, 8.0)	1'', 3''
6''	—	—	6.82 (overlap)	2'', 4'', 7''
7''	—	—	4.97 (d, 5.0)	1'', 2'', 6'', 8'', 9''
8''	—	—	4.24 m	4'


Table 1 (continued)

Position	1		2	
	δ _H	HMBC	δ _H	HMBC
9''a	—	—	3.90 m	7''
9''b	—	—	3.58 (dd, 12.0, 3.5)	—
3-OCH ₃	—	—	3.88 s	3
3'-OCH ₃	—	—	3.87 s	3'
3''-OCH ₃	—	—	3.86 s	3''
-OCH ₂ O-	5.95 s	3	—	—

^a Assignments were based on HMQC, and HMBC experiments.

The configuration of **1** was determined on the basis of the NOESY correlations [H-7/H-9b, H-8/H-9a, H-9b/H-7', H-7'/H-9'a] (Fig. 3) and positive optical rotation value ([α]_D²⁵ +18.0, CH₃OH) in comparison to (+)-syringaresinol.¹⁴ Thus, the structure of **1** was established to be (+)-8'-hydroxybeechnol, and was named firmianol A.

Compound **2** was obtained as a colorless gum. The molecular formula of **2** was determined to be C₃₁H₃₅O₁₂ by the positive mode HR-FABMS data at *m/z* 623.2100 [M+Na]⁺ (calcd for C₃₁H₃₅O₁₂Na, 623.2099). Its NMR spectra were analogous to those of (+)-1-hydroxypinoresinol, which was isolated from *Saussurea pulchella*,¹⁵

Figure 2. Key COSY (bold line) and HMBC (arrow) correlations of **1** and **2**.




Figure 3. Key NOESY correlations of **1**.

Table 2
¹³C NMR data of compounds **1** and **2** (CD₃OD, 175 MHz, δ in ppm, J in Hz)^a

δ _C	1	2
1	136.5	133.7
2	107.8	111.2
3	149.5	149.1
4	148.8	147.4
5	109.0	116.0
6	121.0	120.4
7	87.5	87.8
8	62.6	62.6
9	72.1	72.3
1'	128.5	134.2
2'	130.9	106.2
3'	115.8	154.3
4'	158.5	136.3
5'	115.8	154.3
6'	130.9	106.2
7'	89.2	89.2
8'	92.7	93.2
9'	76.3	76.2
1''		133.9
2''		111.2
3''		148.7
4''		146.8
5''		115.7
6''		120.4
7''		74.1
8''		87.7
9''		61.6
3-OCH ₃		56.8
3'-OCH ₃		56.8
3''-OCH ₃		56.3
-OCH ₂ O-	102.4	-

^a Assignments were based on HMQC, and HMBC experiments.

Table 3
 Inhibitory effect on NO production of compounds **1–19** in LPS-activated BV-2 cells

Compounds	IC ₅₀ ^a (μM)	Cell viability ^b (%)
Firmianol A (1)	35.39	109 ± 3.6
Firmianol B (2)	>500	108.5 ± 3.9
(+)-Piperitol (3)	32.65	113. ± 9.4
(+)-Pinoresinol (4)	25.1	114.8 ± 5.8
(+)-Syringaresinol (5)	27.53	110.1 ± 7.5
Buddlenol E (6)	19.33	121 ± 8.5
(1S*,2R*,5R*,6S*)-6-(4-Hydroxy-3-methoxy-phenyl)-2-(3,4-methoxylenedioxyphenyl)-3,7-dioxibicyclo[3.3.0]-octan-1-ol (7)	>500	108 ± 6.7
(+)-Sesamin (8)	26.26	126 ± 5.3
(-)-Pinoresinol (9)	31.1	111.1 ± 6.1
(+)-7'-Methoxyariciresinol (10)	32.99	115 ± 5.5
Balanophonin (11)	7.07	115. ± 5.9
(-)-5-Methoxybalanophonin (12)	10.0	119.5 ± 5.5
Buddlenol A (13)	15.28	129 ± 10.0
<i>threo</i> -(7 <i>R</i> ,8 <i>R</i>)-Guaiacylglycerol-β-coniferyl aldehyde ether (14)	1.05	122.6 ± 4.8
<i>erythro</i> -(7 <i>S</i> ,8 <i>R</i>)-Guaiacylglycerol-β-coniferyl aldehyde ether (15)	0.929	128.9 ± 6.3
<i>threo</i> -Guaiacylglycerol-8- <i>O</i> -4'-sinapyl alcohol ether (16)	23.53	120.2 ± 3.3
<i>erythro</i> -Syringylglycerol-8- <i>O</i> -4'-coniferyl alcohol ether (17)	9.14	123.4 ± 4.2
<i>threo</i> -Guaiacylglycerol-8- <i>O</i> -4'-coniferyl alcohol ether (18)	32.56	116.8 ± 4.8
<i>threo</i> -Guaiacylglycerol 8'-vanillin ether (19)	47.59	116.4 ± 6.9
NMMA ^c	16.27	98.2 ± 2.6

^a IC₅₀ value of each compound was defined as the concentration (μM) that caused 50% inhibition of NO production in LPS-activated BV-2 cells.

^b Cell viability after treatment with 20 μM of each extract was expressed as a percentage (%) of the LPS only treatment group. The results are averages of three independent experiments, and the data are expressed as mean ± SD.

^c NMMA as a positive control.

except for the additional guaiacylglycerol moiety [δ_{H} 7.03 (1H, s, H-2''), 6.82 (1H, overlap, H-6''), 6.77 (1H, d, $J = 8.0$ Hz, H-5''), 4.97 (1H, d, $J = 5.0$ Hz, H-7''), 4.24 (1H, m, H-8''), 3.90 (1H, m, H-9''a), 3.58 (1H, dd, $J = 12.0, 3.5$ Hz, H-9''b), and 3.86 (3H, s, 3''-OCH₃) in the ¹H NMR; δ_{C} 148.7 (C-3''), 146.8 (C-4''), 133.9 (C-1''), 120.4 (C-6''), 115.7 (C-5''), 111.2 (C-2''), 87.7 (C-8''), 74.1 (C-7''), 61.6 (C-9''), 56.3 (3''-OCH₃) in the ¹³C NMR]. The location of the guaiacylglycerol group was deduced to be at C-4' by analysis of the HMBC data showing correlation from H-8'' to C-4' (Fig. 2). The configuration of two aryl substituents in **2** was identified to be the same as **1** by NOESY correlation and positive optical rotation value ($[\alpha]_{\text{D}}^{25} + 8.8, \text{CH}_3\text{OH}$). The small coupling constant for $J_{7''/8''}$ (5.0 Hz) in guaiacylglycerol moiety indicated an *erythro* configuration. The CD spectrum exhibited the positive cotton effect at 240 nm confirming the absolute configurations as 7''*R* and 8''*S*.¹⁶ Thus, the structure of **2** was determined as shown in Figure 1, and was named firmianol B.

The known structures **3–19** were confirmed as (+)-piperitol (**3**),¹⁷ (+)-pinoresinol (**4**),¹⁷ (+)-syringaresinol (**5**),¹⁸ buddlenol E (**6**),¹⁹ (1*S**,2*R**,5*R**,6*S**)-6-(4-hydroxy-3-methoxyphenyl)-2-(3,4-methoxylenedioxyphenyl)-3,7-dioxibicyclo[3.3.0]-octan-1-ol (**7**),²⁰ (+)-sesamin (**8**),¹⁷ (-)-pinoresinol (**9**),²¹ (+)-7'-methoxyariciresinol (**10**),²² balanophonin (**11**),²³ (-)-5-methoxybalanophonin (**12**),²⁴ buddlenol A (**13**),²⁵ *threo*-(7*R*,8*R*)-guaiacylglycerol-β-coniferyl aldehyde ether (**14**),²⁶ *erythro*-(7*S*,8*R*)-guaiacylglycerol-β-coniferyl aldehyde ether (**15**),²⁶ *threo*-guaiacylglycerol-8-*O*-4'-sinapyl alcohol ether (**16**),²⁷ *erythro*-syringylglycerol-8-*O*-4'-coniferyl alcohol ether (**17**),²⁷ *threo*-guaiacylglycerol-8-*O*-4'-coniferyl alcohol ether (**18**),²⁷ and *threo*-guaiacylglycerol 8'-vanillin ether (**19**)²⁸ by comparing their spectroscopic data with the reported data (Supplementary data).

Microglia cells are considered to be the major immune cells that play a crucial role in inflammatory, immune and degenerative processes in the brain.³ In order to determine the potential antineuroinflammatory properties of isolated lignans, compounds (**1–19**) were tested for their inhibitory effect on lipopolysaccharide (LPS)-stimulated nitric oxide (NO) production in microglia cells. In this study, compounds **14** and **15** strongly inhibited NO levels in LPS-stimulated BV-2 without cell toxicity (IC₅₀ value of 1.05 and 0.929 μM, respectively) (Table 3). Similarly, compounds **11–13** and **17** also exhibited IC₅₀ values ranging from 7.07 to

15.28 μM which were less than the value of the positive control N^G -Mono-methyl-L-arginine (L-NMMA). The presence of α,β -unsaturated aldehyde group in these lignans played an especially important role in the compounds, anti-inflammatory properties.

In conclusion, our current study indicates that these isolated lignan compounds from *F. simplex* may be candidates as anti-neuroinflammatory agents with the potential to be therapeutic agents in the treatment of neurodegenerative diseases.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2013R1A1A2A10005315). We are thankful to the Korea Basic Science Institute (KBSI) for the MS spectra measurements.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2016.01.008>.

References and notes

- Ghosh, S.; Basu, A. *Drug Discovery Today* **2012**, *17*, 600.
- Li, T.; Pang, S.; Yu, Y.; Wu, X.; Guo, J.; Zhang, S. *Brain* **2013**, *136*, 3578.
- Minghetti, L.; Levi, G. *Prog. Neurobiol.* **1998**, *54*, 99.
- Kim, K. H.; Choi, J. W.; Ha, S. K.; Kim, S. Y.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 409.
- Kim, K. H.; Choi, J. W.; Choi, S. U.; Ha, S. K.; Kim, S. Y.; Park, H. J.; Lee, K. R. *J. Enzyme Inhib. Med. Chem.* **2011**, *26*, 254.
- Woo, K. W.; Moon, E.; Park, S. Y.; Kim, S. Y.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7465.
- Lee, S. Y.; Moon, E.; Kim, S. Y.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2140.
- Woo, K. W.; Kwon, O. W.; Kim, S. Y.; Choi, S. Z.; Son, M. W.; Kim, K. H.; Lee, K. R. *J. Ethnopharmacol.* **2014**, *155*, 1164.
- Lee, Y. N. *Flora of Korea*; Koy-Hak Publishing: Korea, 1996.
- Zhang, L. X.; Song, J. H.; Shen, J. T.; Tan, G. J.; Li, S. S.; Ding, F. J. *Phytopathol.* **2013**, *161*, 128.
- Son, Y. K.; Lee, M. H.; Han, Y. N. *Arch. Pharm. Res.* **2005**, *28*, 34.
- Woo, K. W.; Choi, S. U.; Kim, K. H.; Lee, K. R. *Braz. Chem. Soc.* **2015**, *26*, 1450.
- Cheng, M. J.; Wu, C. C.; Tsai, I. L.; Chen, I. S. *J. Chin. Chem. Soc.* **2004**, *51*, 1065.
- Sumioka, H.; Harinantenaina, L.; Matsunami, K.; Otsuka, H.; Kawahata, M.; Yamaguchi, K. *Phytochemistry* **2011**, *72*, 2165.
- Yang, M. C.; Lee, K. H.; Kim, K. H.; Choi, S. U.; Lee, K. R. *Arch. Pharm. Res.* **2007**, *30*, 1067.
- Gan, M.; Zhang, Y.; Lin, S.; Liu, M.; Song, W.; Zi, J.; Yang, Y.; Fan, X.; Shi, J.; Hu, J.; Sun, J.; Chen, N. *J. Nat. Prod.* **2008**, *71*, 647.
- Takaku, N.; Mikame, K.; Okunishi, T.; Suzuki, S.; Umezawa, T.; Shimada, M. *J. Wood Sci.* **2001**, *47*, 476.
- Lee, S. Y.; Woo, K. W.; Kim, C. S.; Lee, D. U.; Lee, K. R. *Helv. Chim. Acta* **2013**, *96*, 320.
- Houghton, P. J. *Phytochemistry* **1985**, *24*, 819.
- Yamauchi, S.; Ina, T.; Kirikihira, T.; Masuda, T. *Biosci. Biotechnol. Biochem.* **2004**, *68*, 183.
- Ouyang, M. A.; Wein, Y. S.; Zhang, Z. K.; Kuo, Y. H. *J. Agric. Food Chem.* **2007**, *55*, 6460.
- Sun, Y. J.; Li, Z. L.; Chen, H.; Liu, X. Q.; Zhou, W.; Hua, H. M. *Planta Med.* **2012**, *78*, 480.
- Li, S. H.; Zhang, H. J.; Niu, X. M.; Yao, P.; Sun, H. D.; Fong, H. H. S. *J. Nat. Prod.* **2003**, *66*, 1002.
- Chen, J. J.; Chen, P. H.; Liao, C. H.; Huang, S. Y.; Chen, I. S. *J. Nat. Prod.* **2007**, *70*, 1444.
- Yang, X. W.; Zhao, P. J.; Ma, Y. L.; Xiao, H. T.; Zuo, Y. Q.; He, H. P.; Li, L.; Hao, X. J. *J. Nat. Prod.* **2007**, *70*, 521.
- Huang, X. X.; Zhou, C. C.; Li, L. Z.; Li, F. F.; Lou, L. L.; Li, D. M.; Ikejima, T.; Peng, Y.; Song, S. J. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5599.
- Lourith, N.; Katayama, T.; Suzuki, T. *J. Wood Sci.* **2005**, *51*, 370.
- Sakushima, A.; Ohno, K.; Maoka, T.; Coskun, M.; Guvenc, A.; Erdurak, C. S.; Ozkan, A. M.; Seki, K. I.; Ohkura, K. *Phytochem. Anal.* **2003**, *14*, 48.